Detalhe da pesquisa
1.
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.
Mol Ther;
30(5): 1885-1896, 2022 05 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34687845
2.
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
Mol Ther;
30(9): 2998-3016, 2022 09 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35526097
3.
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.
Mol Ther;
29(6): 1984-2000, 2021 06 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33578036
4.
Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment.
Front Immunol;
14: 1099459, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36969187
5.
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.
Front Immunol;
13: 1050250, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36713447
6.
SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.
Biosens Bioelectron;
180: 113122, 2021 05 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33706157